Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Beijing Huaru Technology
301302
5
Jiangxi Welgao Electronics
301251
US OptionsDetailed Quotes
CRDF250516P2000
- 0.00
- 0.000.00%
15min DelayClose May 9 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV24.81%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma10.64Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cardiff Oncology Newsroom
H.C. Wainwright Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Raises Target Price to $18
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Announces Target Price $10
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $10
Cardiff Oncology Is Maintained at Buy by HC Wainwright & Co.
Cardiff Oncology Analyst Ratings
William Blair Maintains Cardiff Oncology(CRDF.US) With Buy Rating
TD Cowen Maintains Cardiff Oncology(CRDF.US) With Buy Rating
William Blair Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Cardiff Oncology (CRDF), UnitedHealth (UNH) and McKesson (MCK)
Piper Sandler Initiates Cardiff Oncology(CRDF.US) With Buy Rating, Announces Target Price $10
Lucid Capital Initiates Cardiff Oncology(CRDF.US) With Buy Rating, Announces Target Price $14
Cardiff Oncology Initiated With a Buy at Lucid Capital
H.C. Wainwright Initiates Cardiff Oncology(CRDF.US) With Buy Rating, Announces Target Price $17
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $10
A Quick Look at Today's Ratings for Cardiff Oncology(CRDF.US), With a Forecast Between $10 to $17
Cardiff Oncology Is Maintained at Buy by HC Wainwright & Co.
Cardiff Oncology Analyst Ratings
Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Cardiff Oncology (CRDF)
William Blair Keeps Their Buy Rating on Cardiff Oncology (CRDF)
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
